Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Neoglycyrol shows some cardioprotective effects .
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 57.00 | |
5 mg | In stock | $ 128.00 | |
10 mg | In stock | $ 190.00 | |
25 mg | In stock | $ 318.00 | |
50 mg | In stock | $ 469.00 | |
100 mg | In stock | $ 689.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 140.00 |
Description | Neoglycyrol shows some cardioprotective effects . |
In vitro | Fractions of TMYXP were prepared by high performance liquid preparation technology. The cardioprotective effects of prepared fractions were tested on H2O2 oxidation-damaged H9c2 myocardiocytes. The active components were analyzed by high performance liquid chromatography (HPLC) coupled with high resolution mass spectrometry. The possible active compounds were putatively identified by comparison of their MS ions and molecular weight with literatures. Ten TMYXP components presented significant myocardial protective activities, 5 of which were investigated and presented good dose-effect relationships. Their median effective concentrations (EC50) were respectively 11.66, 17.44, 13.10, 7.332, 15.15 μg/mL. Totally, 11 potential active compounds were analyzed and identified, including Glycyrrhizic acid, Glycycoumarin, Licoisoflavone, Ophiopogonin D', Licoricon, Gancaonin L, Neoglycyrol, Emodin, Angeloylgomisin H, Angeloylgomisin Q and Glyasperin A. |
Source |
Molecular Weight | 366.36 |
Formula | C21H18O6 |
CAS No. | 23013-84-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.66 mg/mL (10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Neoglycyrol 23013-84-5 Others Inhibitor inhibit inhibitor